These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 17631131

  • 1. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
    Hawkey CJ, Weinstein WM, Smalley W, Gitton X, Sallstig P, Stricker K, Krammer G, Mellein B, Richard D, Matchaba P.
    Gastroenterology; 2007 Jul; 133(1):57-64. PubMed ID: 17631131
    [Abstract] [Full Text] [Related]

  • 2. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
    Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ, TARGET Study Group.
    Lancet; 2007 Jul; 364(9435):665-74. PubMed ID: 15325831
    [Abstract] [Full Text] [Related]

  • 3. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH, TARGET Study Group.
    Lancet; 2007 Jul; 364(9435):675-84. PubMed ID: 15325832
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FW, Chesebro JH, Kirshner H, Hochman JS, Lay CL, Ruland S, Mellein B, Matchaba PT, Fuster V, Abramson SB.
    Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
    [Abstract] [Full Text] [Related]

  • 5. Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial.
    Hawkey CJ, Weinstein WM, Stricker K, Murphy V, Richard D, Krammer G, Rebuli R.
    Aliment Pharmacol Ther; 2008 May; 27(9):838-45. PubMed ID: 18221410
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
    Hawkey CJ, Farkouh M, Gitton X, Ehrsam E, Huels J, Richardson P.
    Aliment Pharmacol Ther; 2004 Jul 01; 20(1):51-63. PubMed ID: 15225171
    [Abstract] [Full Text] [Related]

  • 7. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
    Bannwarth B, Berenbaum F.
    Expert Opin Investig Drugs; 2005 Apr 01; 14(4):521-33. PubMed ID: 15882125
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.
    Clin Ther; 2005 Aug 01; 27(8):1196-214. PubMed ID: 16199245
    [Abstract] [Full Text] [Related]

  • 9. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
    Hawkey CJ, Gitton X, Hoexter G, Richard D, Weinstein WM.
    Clin Gastroenterol Hepatol; 2006 Jan 01; 4(1):57-66. PubMed ID: 16431306
    [Abstract] [Full Text] [Related]

  • 10. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
    MacDonald TM, Reginster JY, Littlejohn TW, Richard D, Lheritier K, Krammer G, Rebuli R.
    J Hypertens; 2008 Aug 01; 26(8):1695-702. PubMed ID: 18622250
    [Abstract] [Full Text] [Related]

  • 11. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL, Cryer B, Amer F, Hunt B.
    Clin Gastroenterol Hepatol; 2007 Oct 01; 5(10):1167-74. PubMed ID: 17916545
    [Abstract] [Full Text] [Related]

  • 12. Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials.
    Bello AE, Kent JD, Grahn AY, Rice P, Holt RJ.
    Postgrad Med; 2014 Jul 01; 126(4):82-91. PubMed ID: 25141246
    [Abstract] [Full Text] [Related]

  • 13. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.
    Am J Gastroenterol; 2003 Aug 01; 98(8):1725-33. PubMed ID: 12907325
    [Abstract] [Full Text] [Related]

  • 14. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.
    Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, Rainoldi JL, Szczepanski L, Ung KA, Kleczkowski D, Ahlbom H, Naesdal J, Hawkey C.
    Am J Gastroenterol; 2006 Apr 01; 101(4):701-10. PubMed ID: 16494585
    [Abstract] [Full Text] [Related]

  • 15. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
    Goldstein JL, Lowry SC, Lanza FL, Schwartz HI, Dodge WE.
    Aliment Pharmacol Ther; 2006 May 15; 23(10):1489-98. PubMed ID: 16669964
    [Abstract] [Full Text] [Related]

  • 16. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population.
    García Rodríguez LA, Barreales Tolosa L.
    Gastroenterology; 2007 Feb 15; 132(2):498-506. PubMed ID: 17258728
    [Abstract] [Full Text] [Related]

  • 17. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
    Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL.
    Lancet; 2010 Jul 17; 376(9736):173-9. PubMed ID: 20638563
    [Abstract] [Full Text] [Related]

  • 18. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, MEDAL Steering Committee.
    Lancet; 2007 Feb 10; 369(9560):465-73. PubMed ID: 17292766
    [Abstract] [Full Text] [Related]

  • 19. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.
    Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C.
    Aliment Pharmacol Ther; 2004 Jun 01; 19(11):1189-98. PubMed ID: 15153172
    [Abstract] [Full Text] [Related]

  • 20. A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.
    Farkouh ME, Verheugt FW, Ruland S, Kirshner H, Jeger R, Gitton X, Krammer G, Stricker K, Sallstig P, Mellein B, Matchaba P, Chesebro JH.
    J Clin Hypertens (Greenwich); 2008 Aug 01; 10(8):592-602. PubMed ID: 18772641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.